Carcinogenesis, Vol. 23, No. 6, 1017-1024,
June 2002
© 2002 Oxford University Press
CARCINOGENESIS |
Inhibitor of apoptosis protein-1 promotes tumor cell survival in mesothelioma
Division of Thoracic Surgery, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
Malignant pleural mesothelioma (MPM) is a highly lethal pleural neoplasm that is often resistant to chemotherapeutic drugs, including cisplatin, and for which little is known regarding carcinogenic pathways. We used differential display to compare gene expression patterns in mesothelioma, normal pleura and normal lung, in order to better understand MPM pathobiology, and to search for genes that may facilitate drug resistance in this cancer. The human inhibitor of apoptosis protein-1 gene (IAP-1/MIHC/cIAP2) was discovered to be highly expressed in MPM. We confirmed overexpression of IAP-1 mRNA and protein in 39 additional human MPM tumor specimens and 3/5 (60%) MPM cell lines by multiple methods, including real time quantitative reverse transcription–PCR and western blot analysis. Using an antisense targeting approach, we found that attenuation of IAP-1 mRNA levels decreases baseline cell viability and increases the sensitivity of MPM cell lines to cisplatin by nearly 20-fold. Reduced IAP-1 gene expression also results in a concordant increase of the pro-apoptotic cleavage product of caspase 9 and a reduction in the number of viable tumor cells. Our observations strongly suggest that IAP-1 is at least partly responsible for promoting carcinogenesis and mediating resistance to cisplatin in many MPM tumors and that further study of this apoptotic pathway is warranted.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  Z. Q. Yuan, L. Nicolson, B. Marchetti, E. A. Gault, M. S. Campo, and L. Nasir Transcriptional Changes Induced by Bovine Papillomavirus Type 1 in Equine Fibroblasts J. Virol., July 1, 2008; 82(13): 6481 - 6491. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. W. Sherrill and R. E. Lloyd Translation of cIAP2 mRNA Is Mediated Exclusively by a Stress-Modulated Ribosome Shunt Mol. Cell. Biol., March 15, 2008; 28(6): 2011 - 2022. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Sugarbaker, W. G. Richards, G. J. Gordon, L. Dong, A. De Rienzo, G. Maulik, J. N. Glickman, L. R. Chirieac, M.-L. Hartman, B. E. Taillon, et al. Transcriptome sequencing of malignant pleural mesothelioma tumors PNAS, March 4, 2008; 105(9): 3521 - 3526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Vucic and W. J. Fairbrother The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer Clin. Cancer Res., October 15, 2007; 13(20): 5995 - 6000. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Flynn, R. W. Berg, T. Wong, M. van Aken, M. D. Vincent, M. Fukushima, and J. Koropatnick Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma. Mol. Cancer Ther., June 1, 2006; 5(6): 1423 - 1433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mukohara, G. Civiello, I. J. Davis, M. L. Taffaro, J. Christensen, D. E. Fisher, B. E. Johnson, and P. A. Janne Inhibition of the Met Receptor in Mesothelioma Clin. Cancer Res., November 15, 2005; 11(22): 8122 - 8130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Reed and M. Pellecchia Apoptosis-based therapies for hematologic malignancies Blood, July 15, 2005; 106(2): 408 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Gordon, G. N. Rockwell, R. V. Jensen, J. G. Rheinwald, J. N. Glickman, J. P. Aronson, B. J. Pottorf, M. D. Nitz, W. G. Richards, D. J. Sugarbaker, et al. Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling Am. J. Pathol., June 1, 2005; 166(6): 1827 - 1840. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Z. Carter, M. Gronda, Z. Wang, K. Welsh, C. Pinilla, M. Andreeff, W. D. Schober, A. Nefzi, G. R. Pond, I. A. Mawji, et al. Small-molecule XIAP inhibitors derepress downstream effector caspases and induce apoptosis of acute myeloid leukemia cells Blood, May 15, 2005; 105(10): 4043 - 4050. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Wang, M. Cuddy, T. Samuel, K. Welsh, A. Schimmer, F. Hanaii, R. Houghten, C. Pinilla, and J. C. Reed Cellular, Biochemical, and Genetic Analysis of Mechanism of Small Molecule IAP Inhibitors J. Biol. Chem., November 12, 2004; 279(46): 48168 - 48176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Krajewska, S. Krajewski, S. Banares, X. Huang, B. Turner, L. Bubendorf, O.-P. Kallioniemi, A. Shabaik, A. Vitiello, D. Peehl, et al. Elevated Expression of Inhibitor of Apoptosis Proteins in Prostate Cancer Clin. Cancer Res., October 15, 2003; 9(13): 4914 - 4925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Singhal, R. Wiewrodt, L. D. Malden, K. M. Amin, K. Matzie, J. Friedberg, J. C. Kucharczuk, L. A. Litzky, S. W. Johnson, L. R. Kaiser, et al. Gene Expression Profiling of Malignant Mesothelioma Clin. Cancer Res., August 1, 2003; 9(8): 3080 - 3097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Dai, W.-G. Zhu, C. D. Morrison, R. M. Brena, D. J. Smiraglia, A. Raval, Y.-Z. Wu, L. J. Rush, P. Ross, J. R. Molina, et al. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes Hum. Mol. Genet., April 1, 2003; 12(7): 791 - 801. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Hunter, D. Kottachchi, J. Lewis, C. S. Duckett, R. G. Korneluk, and P. Liston A Novel Ubiquitin Fusion System Bypasses the Mitochondria and Generates Biologically Active Smac/DIABLO J. Biol. Chem., February 21, 2003; 278(9): 7494 - 7499. [Abstract] [Full Text] [PDF]
|
|